All News
CORRONA Presentations at ACR 2016
CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.
Read Article
Two New Biologics for Polyarticular JIA
On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.
Read Article
SPIRIT P1 Study - Ixekinumab Sustains Efficacy at 52 Weeks in Psoriatic Arthritis
Ixekinumab (IXE) is an IGG4 monoclonal antibody bindings with high affinity to IL -17A. Currently marketed at Taltz and approved for use in chronic plaque psoriasis, the agent is also being developed for use in psoriatic arthritis.
Read Article
Anti-IL-6 therapy shows promise in GCA
The opening day plenary session at ACR 2016 this morning featured John H.
Read Article
Termination of TCZ in GCA
Treatment of giant cell arteritis with tocilizumab is a hot topic at this year’s ACR meeting and, while GiACTA data was promising, a Swiss study reported less-favorable results at the poster session this morning (
Read Article
Unmet Needs: Prediction and early detection in SpA first-degree relatives
Why do diseases manifest in some family members but not in others? Antibodies can be found in patients who do not meet criteria for treatment, especially in first-degree relatives.
Read Article
RheumNow Week in Review – 11 November 2016
Dr Cush reviews highlights from this week on RheumNow.com
Read Article
The ACR 2016 Playbook
For me and many others, this is the Super Bowl of meetings. I haven’t missed an ACR meeting since I started going as a fellow in 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 14,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, a gigantic Costco (on Saturday), and a sold-out concert.
Read Article
The Long Awaited PRECISION Study
The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.
Read Article
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
Janssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read Article
Creaky Joints Presentations at the ACR16 Meeting
CreakyJoints will be presenting 5 Posters at the 2016 ACR/AHRP Annual Meeting. At the meeting they will also announce the publication of first-ever Rheumatoid Arthritis Patient Guidelines.
Read Article
Amgen Highlights Enbrel, Prolia and Amjevita Research at ACR 2016
Amgen has released the presentation times and locations for 21 abstracts to be presented at the ACR/ARHP 2016 Annual Meeting in Washington next week.
Read Article
Genentech Presents New Data on Actemra & Rituxan at ACR 2016
At the upcoming 2016 ACR/ARHP Annual Meeting, Genentech will present 15 oral presentations from 17 abstracts relating to the use of tocilizumab and rituximab in a number of varied autoimmune conditions.
Read Article
Crescendo and Vectra Presentations at ACR 2016
Crescendo Bioscience has announced that it will have 4 poster presentations at the American College of Rheumatology 2016 Annual Meeting next week.
Read Article
10 Tips for Immunization in Practice
Dr. Jerome Greenberg from UCLA has published 10 tips and pearls (based on years of teaching and experience) on immunizations in an out-patient practice:
Read Article
Agressive Early Treatment Prevents Rapid Bone Loss in Rheumatoid Arthritis
The International Osteoporosis Foundation has established the Chronic Inflammation and Bone Structure (CIBS) Working Group to address bone loss in rheumatoid arthritis (RA) and the role of biologic therapies. They conclude that early and aggressive treatment with biologic disease-modifying anti-rheumatic drugs will help prevent progressive bone loss in patients with RA.
Read Article
Do Statins Reduce Cardiovascular Disease in Rheumatoid Arthritis?
RA increases CV risk considerably. But whose responsibility is it to manage CV risk in RA patients?
Read Article
Enbrel Approved for Pediatric Chronic Plaque Psoriasis
Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis. Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.
Read Article